XEXeris Biopharma Holdings, Inc. XERS · NASDAQ
$10.71 -0.37% (-$0.04)
- Market cap
- $1.96B
- Enterprise value
- $2.13B
- P/E
- -
- Forward P/E
- 2,170.5x
- PEG
- -
- P/S
- 5.8x
- P/FCF
- 35.4x
- EV/EBITDA
- 129.6x
- ROIC
- 12.5%
- Bruto marža
- 83.3%
- Neto marža
- -5.1%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- 10.2x
- Beta
- 0.84
- Free float
- 94.9%
O podjetju
Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company focused on developing innovative therapeutic treatments for patients with metabolic disorders and endocrine diseases. Their main focus is on developing fixed-dose formulations of therapeutic drugs that can improve patients' quality of life and simplify their treatment regimen. Xeris Biopharma concentrates on areas such as diabetic hypoglycemia, type 1 and 2 diabetes, and adrenal insufficiency. The company is known for its innovative technologies in drug formulation and applications for patients with chronic conditions. Shares of Xeris Biopharma Holdings, Inc. (XERS) may be suitable for investors seeking opportunities in the biotechnology sector with potential for innovative treatments and growth prospects.
Sector
Healthcare
Industry
Biotechnology
CEO
John Shannon
Employees
435
Headquarters
Chicago
Vrednotenje
Je današnja cena primerna?
- Kaj govori v prid: Cena delnice je pod Bulios Fair Price.
Rast in ocene
Ali podjetje raste in kaj sledi?
- Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 38 % letno.
- Kaj govori v prid: Analitiki v tem poslovnem letu pričakujejo rast prihodkov za 33 %.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Kaj govori v prid: Od vsakih 100 USD prihodkov ostane 17 USD prostega denarja.
- Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.
Finančno zdravje
Ali zmore svoj dolg?
- Na kaj bodite pozorni: Poslovni dobiček ne pokrije niti obresti na dolg.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke